StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

CRISPR Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $278.15M, down 6.1% year over year. For fiscal 2025 it was $284.81M, down 8.2% from the year before. Over ten years it grew 36.6% a year on average. The highest annual figure on record is $461.65M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$284.81M-8.2%
FY2024Dec 31, 2024$310.24M-19.9%
FY2023Dec 31, 2023$387.33M-16.1%
FY2022Dec 31, 2022$461.65M+35.6%
FY2021Dec 31, 2021$340.57M+53.8%
FY2020Dec 31, 2020$221.38M+23.4%
FY2019Dec 31, 2019$179.36M+57.6%
FY2018Dec 31, 2018$113.77M+63.0%
FY2017Dec 31, 2017$69.80M+65.3%
FY2016Dec 31, 2016$42.24M+235.9%
FY2015Dec 31, 2015$12.57M+731.0%
FY2014Dec 31, 2014$1.51M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$67.15M-3.9%
Q1 FY2026Mar 31, 2026$68.57M-5.4%
Q4 FY2025Dec 31, 2025$83.53M+16.4%
Q3 FY2025Sep 30, 2025$58.90M-28.3%
Q2 FY2025Jun 30, 2025$69.89M-12.8%
Q1 FY2025Mar 31, 2025$72.48M-4.8%
Q4 FY2024Dec 31, 2024$71.74M-24.6%
Q3 FY2024Sep 30, 2024$82.16M-9.4%
Q2 FY2024Jun 30, 2024$80.17M-21.1%
Q1 FY2024Mar 31, 2024$76.17M-23.8%
Q4 FY2023Dec 31, 2023$95.14M-8.1%
Q3 FY2023Sep 30, 2023$90.70M-22.2%
Q2 FY2023Jun 30, 2023$101.56M-17.6%
Q1 FY2023Mar 31, 2023$99.94M-15.5%
Q4 FY2022Dec 31, 2022$103.56M+0.4%
Q3 FY2022Sep 30, 2022$116.62M+39.7%
Q2 FY2022Jun 30, 2022$123.22M+49.7%
Q1 FY2022Mar 31, 2022$118.25M+67.4%
Q4 FY2021Dec 31, 2021$103.10M+180.1%
Q3 FY2021Sep 30, 2021$83.50M+17.6%
Q2 FY2021Jun 30, 2021$82.33M+38.7%
Q1 FY2021Mar 31, 2021$70.62M+30.3%
Q4 FY2020Dec 31, 2020$36.80M-24.5%
Q3 FY2020Sep 30, 2020$71.01M+24.0%
Q2 FY2020Jun 30, 2020$59.38M+50.2%
Q1 FY2020Mar 31, 2020$54.19M+60.2%
Q4 FY2019Dec 31, 2019$48.76M+69.3%
Q3 FY2019Sep 30, 2019$57.25M+43.8%
Q2 FY2019Jun 30, 2019$39.53M+54.2%
Q1 FY2019Mar 31, 2019$33.82M+73.3%
Q4 FY2018Dec 31, 2018$28.80M+43.8%
Q3 FY2018Sep 30, 2018$39.82M+123.1%
Q2 FY2018Jun 30, 2018$25.63M+49.7%
Q1 FY2018Mar 31, 2018$19.52M+31.8%
Q4 FY2017Dec 31, 2017$20.03M+28.6%
Q3 FY2017Sep 30, 2017$17.85M+48.1%
Q2 FY2017Jun 30, 2017$17.12M–
Q1 FY2017Mar 31, 2017$14.81M–
Q4 FY2016Dec 31, 2016$15.57M–
Q3 FY2016Sep 30, 2016$12.05M–

More CRISPR Therapeutics figures

See a number that looks wrong?